January 6, 2017

Alexion antibody wins FDA orphan drug status

PHOTO | Contributed
PHOTO | Contributed
The building at 100 College St. in New Haven is headquarters for Alexion Pharmaceuticals.

The U.S. Food and Drug Administration has designated as an orphan drug an Alexion Pharmaceuticals' long-acting antibody that may be used to treat a rare blood disorder.

The so-called ALXN1210 biologic developed by the New Haven-based firm is an antibody being evaluated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare, life-threatening blood disorder in which a patient's red blood cells are destroyed.

The FDA, through its Office of Orphan Products Development (OOPD), grants orphan status to drugs that are intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S.

The status provides the developer with benefits and incentives, including a period of marketing exclusivity if the drug receives regulatory approval.

Free E-Newsletters

Sign up now for our daily and weekly
e-newsletters! Click Here

Today's Poll Will state lawmakers raise taxes in 2017 to balance the budget?<>
Most Popular on Facebook
Copyright 2017 New England Business Media